Philip Hublitz

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 9

Top Topics

Immune Response

Top Venues

Methods and protocols

Cancer research

Science advances

Scientific reports

This page only lists publications with an associated author ORCID identifier.

Publications

Zijing Wang, Nan Zhang, Miao Zhang, Yao Jiang, Aik Seng Ng, Esther Bridges, Wei Zhang, Xin Zeng, Qi Luo, Jiabien Liang, Gyorffy Balazs, Philip Hublitz, Zhu Liang, Roman Fischer, David J Kerr, Adrian L Harris, Shijie Cai
GTP cyclohydrolase drives breast cancer development and promotes EMT in an enzyme-independent manner. Cancer research (2023)
Fernando Albericio, Philip Hublitz
Methods and Protocols -Aims and Scope Update. Methods and protocols 6 (6) (2023)
Anna Aulicino, Agne Antanaviciute, Joe Frost, Ana Sousa Geros, Esther Mellado, Moustafa Attar, Marta Jagielowicz, Philip Hublitz, Julia Sinz, Lorena Preciado-Llanes, Giorgio Napolitani, Rory Bowden, Hashem Koohy, Hal Drakesmith, Alison Simmons
Dual RNA sequencing reveals dendritic cell reprogramming in response to typhoidal Salmonella invasion. Communications biology 5 (1) (2022)
Ioanna A Rota, Adam E Handel, Stefano Maio, Fabian Klein, Fatima Dhalla, Mary E Deadman, Stanley Cheuk, Joseph A Newman, Yale S Michaels, Saulius Zuklys, Nicolas Prevot, Philip Hublitz, Philip D Charles, Athina Soragia Gkazi, Eleni Adamopoulou, Waseem Qasim, Edward Graham Davies, Imelda Hanson, Alistair T Pagnamenta, Carme Camps, Helene M Dreau, Andrea White, Kieran D James, Roman Fischer, Opher Gileadi, Jenny C Taylor, Tudor A Fulga, B Christoffer Lagerholm, Graham Anderson, Erdinc Sezgin, Georg A Hollander
FOXN1 forms higher-order nuclear condensates displaced by mutations causing immunodeficiency. Science advances 7 (49) (2021)
Yanchun Peng, Suet Ling Felce, Danning Dong, Frank Penkava, Alexander J Mentzer, Xuan Yao, Guihai Liu, Zixi Yin, Ji-Li Chen, Yongxu Lu, Dannielle Wellington, Peter A C Wing, Delaney C C Dominey-Foy, Chen Jin, Wenbo Wang, Megat Abd Hamid, Ricardo A Fernandes, Beibei Wang, Anastasia Fries, Xiaodong Zhuang, Neil Ashley, Timothy Rostron, Craig Waugh, Paul Sopp, Philip Hublitz, Ryan Beveridge, Tiong Kit Tan, Christina Dold, Andrew John Kwok, Charlotte Rich-Griffin, Wanwisa Dejnirattisa, Chang Liu, Prathiba Kurupati, Isar Nassiri, Robert A Watson, Orion Tong, Chelsea A Taylor, Piyush Kumar Sharma, Bo Sun, Fabiola Curion, Santiago Revale, Lucy C Garner, Kathrin Jansen, Ricardo C Ferreira, Moustafa Attar, Jeremy W Fry, Rebecca A Russell, null null, Hans J Stauss, William S James, Alain Townsend, Ling-Pei Ho, Paul Klenerman, Juthathip Mongkolsapaya, Gavin R Screaton, Calliope Dendrou, Stephen N Sansom, Rachael J M Bashford-Rogers, Benjamin M Chain, Geoffrey L Smith, Jane A McKeating, Benjamin P Fairfax, Paul Bowness, Andrew J McMichael, Graham Ogg, Julian C Knight, Tao Dong
An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nature immunology (2021)
Mirjam Schilling, Anne Bridgeman, Nicki Gray, Jonny Hertzog, Philip Hublitz, Alain Kohl, Jan Rehwinkel
RIG-I Plays a Dominant Role in the Induction of Transcriptional Changes in Zika Virus-Infected Cells, which Protect from Virus-Induced Cell Death. Cells 9 (6) (2020)
Joseph W Blayney, Evangeline M Foster, Marta Jagielowicz, Mira Kreuzer, Matteo Morotti, Katharina Reglinski, Julie Huiyuan Xiao, Philip Hublitz
Unexpectedly High Levels of Inverted Re-Insertions Using Paired sgRNAs for Genomic Deletions. Methods and protocols 3 (3) (2020)
Hedia Chagraoui, Maiken S Kristiansen, Juan Pablo Ruiz, Ana Serra-Barros, Johanna Richter, Elisa Hall-Ponselé, Nicki Gray, Dominic Waithe, Kevin Clark, Philip Hublitz, Emmanouela Repapi, Georg W Otto, Paul Sopp, Stephen Taylor, Supat Thongjuea, Paresh Vyas, Catherine Porcher
SCL/TAL1 cooperates with Polycomb RYBP-PRC1 to suppress alternative lineages in blood-fated cells. Nature communications 9 (1) (2018)
Chi Zhang, Yanchun Peng, Philip Hublitz, Haokang Zhang, Tao Dong
Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy. Scientific reports 8 (1) (2018)